Craig-Hallum analyst Christian Schwab downgraded Teradyne to Hold from Buy and maintained his $42 price target. In a research note to investors, Schwab says he believes share are fully valued at current price levels, as shares are up about 40% since being upgraded in October. Schwab says he will look for a better entry point or improving visibility regarding end market demand before becoming more constructive on shares again. The analyst kept his 2019 revenue and EPS estimates unchanged at $2.061B and $2.08, respectively and his 2020 revenue and EPS estimates unchanged at $2.325B and $2.62, respectively.